Analysts Offer Predictions for TERN Q1 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Terns Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst E. Arce expects that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $7.50 target price on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.28) per share.

Several other equities analysts have also commented on the company. Oppenheimer initiated coverage on Terns Pharmaceuticals in a report on Thursday, October 31st. They set an “outperform” rating and a $82.00 target price for the company. BMO Capital Markets reiterated an “outperform” rating and issued a $26.00 target price (up from $19.00) on shares of Terns Pharmaceuticals in a research note on Monday, September 16th. Finally, JMP Securities upped their price target on shares of Terns Pharmaceuticals from $15.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Tuesday, September 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.25.

Terns Pharmaceuticals Stock Down 5.8 %

Shares of NASDAQ TERN opened at $6.17 on Thursday. The stock’s 50 day moving average price is $8.03 and its two-hundred day moving average price is $7.46. Terns Pharmaceuticals has a 52-week low of $3.59 and a 52-week high of $11.40. The stock has a market capitalization of $524.07 million, a P/E ratio of -5.23 and a beta of -0.32.

Insider Buying and Selling at Terns Pharmaceuticals

In other news, CFO Mark J. Vignola sold 10,000 shares of Terns Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $11.00, for a total value of $110,000.00. Following the transaction, the chief financial officer now directly owns 91,940 shares in the company, valued at approximately $1,011,340. The trade was a 9.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Hongbo Lu purchased 476,190 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $10.50 per share, for a total transaction of $4,999,995.00. Following the completion of the transaction, the director now owns 476,190 shares in the company, valued at approximately $4,999,995. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 15.10% of the company’s stock.

Hedge Funds Weigh In On Terns Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TERN. Janus Henderson Group PLC increased its holdings in shares of Terns Pharmaceuticals by 40.6% during the first quarter. Janus Henderson Group PLC now owns 2,003,263 shares of the company’s stock worth $13,131,000 after buying an additional 578,500 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Terns Pharmaceuticals by 56.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 176,673 shares of the company’s stock valued at $1,203,000 after purchasing an additional 64,018 shares in the last quarter. Russell Investments Group Ltd. raised its position in Terns Pharmaceuticals by 127.9% in the 1st quarter. Russell Investments Group Ltd. now owns 632,965 shares of the company’s stock valued at $4,152,000 after purchasing an additional 355,224 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Terns Pharmaceuticals by 21.1% in the second quarter. Point72 Asset Management L.P. now owns 2,690,376 shares of the company’s stock worth $18,321,000 after purchasing an additional 469,176 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Terns Pharmaceuticals by 0.5% during the first quarter. Vanguard Group Inc. now owns 2,199,006 shares of the company’s stock worth $14,425,000 after purchasing an additional 11,535 shares during the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.